Use of the Lotus Transcatheter Valve to Treat Severe Native Aortic Regurgitation

Smriti Saraf; Muhammed Zeeshan Khawaja; Roland Hilling-Smith; Maureen Dooley; James Cockburn; Uday Trivedi; David Hildick-Smith

doi:10.1016/j.athoracsur.2016.09.017

Use of the Lotus Transcatheter Valve to Treat Severe Native Aortic Regurgitation

Ann Thorac Surg. 2017 Apr;103(4):e305-e307. doi: 10.1016/j.athoracsur.2016.09.017.

Authors

Smriti Saraf¹, Muhammed Zeeshan Khawaja¹, Roland Hilling-Smith¹, Maureen Dooley¹, James Cockburn¹, Uday Trivedi¹, David Hildick-Smith²

Affiliations

¹ Sussex Cardiac Centre, Brighton and Sussex University Hospital, United Kingdom.
² Sussex Cardiac Centre, Brighton and Sussex University Hospital, United Kingdom. Electronic address: david.hildick-smith@bsuh.nhs.uk.

PMID: 28359483
DOI: 10.1016/j.athoracsur.2016.09.017

Abstract

Transcatheter aortic valve implantation (TAVI) has become the standard treatment for aortic stenosis in high-risk patients. TAVI for native valve aortic regurgitation is technically more demanding because of a lack of anchoring calcification, a lower index incidence, heterogeneous causes, and larger anatomy. We present 3 cases in which the Lotus TAV was used to treat severe native aortic regurgitation (AR) successfully.

Publication types

Case Reports

MeSH terms

Aged
Aged, 80 and over
Aortic Valve Insufficiency / diagnostic imaging
Aortic Valve Insufficiency / etiology
Aortic Valve Insufficiency / surgery*
Female
Heart Valve Prosthesis*
Humans
Male
Transcatheter Aortic Valve Replacement / instrumentation*